Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (843) 843
Publication (69) 69
Book Review (8) 8
Book Chapter (5) 5
Conference Proceeding (4) 4
Magazine Article (3) 3
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (750) 750
aminoquinolines - adverse effects (502) 502
female (469) 469
male (451) 451
aminoquinolines - therapeutic use (408) 408
index medicus (373) 373
aminoquinolines - administration & dosage (365) 365
imiquimod (317) 317
middle aged (294) 294
dermatology (281) 281
adult (278) 278
treatment outcome (230) 230
aged (222) 222
administration, topical (198) 198
skin neoplasms - drug therapy (169) 169
animals (159) 159
antineoplastic agents - adverse effects (143) 143
adjuvants, immunologic - adverse effects (140) 140
antineoplastic agents - administration & dosage (136) 136
antineoplastic agents - therapeutic use (134) 134
adjuvants, immunologic - administration & dosage (120) 120
adjuvants, immunologic - therapeutic use (115) 115
aminoquinolines - pharmacology (104) 104
aged, 80 and over (102) 102
care and treatment (97) 97
mice (93) 93
carcinoma, basal cell - drug therapy (92) 92
adolescent (89) 89
administration, cutaneous (88) 88
double-blind (80) 80
skin (77) 77
double-blind method (76) 76
5-percent cream (72) 72
skin neoplasms - pathology (72) 72
drug therapy (71) 71
immunology (70) 70
dose-response relationship, drug (69) 69
drug administration schedule (66) 66
research (64) 64
therapy (64) 64
infectious diseases (62) 62
ointments (62) 62
condylomata acuminata - drug therapy (61) 61
follow-up studies (60) 60
cancer (59) 59
pharmacology & pharmacy (58) 58
dosage and administration (56) 56
actinic keratosis (52) 52
malaria (51) 51
psoriasis (51) 51
topical imiquimod (50) 50
surgery (49) 49
immune-response modifier (47) 47
keratosis, actinic - drug therapy (47) 47
antimalarials - adverse effects (46) 46
carcinoma, basal cell - pathology (46) 46
disease models, animal (46) 46
inflammation (46) 46
interferon inducers - adverse effects (46) 46
skin cancer (46) 46
time factors (46) 46
young adult (46) 46
child (45) 45
health aspects (45) 45
keratosis - drug therapy (44) 44
skin - pathology (44) 44
aminoquinolines - pharmacokinetics (43) 43
analysis (43) 43
cream (43) 43
trial (43) 43
oncology (42) 42
primaquine (42) 42
prospective studies (41) 41
psoriasis - chemically induced (40) 40
interferon inducers - therapeutic use (39) 39
interferon inducers - administration & dosage (37) 37
prolactin - blood (37) 37
efficacy (36) 36
basal cell carcinoma (35) 35
carcinoma, squamous cell - drug therapy (35) 35
safety (35) 35
medicine, general & internal (34) 34
endocrinology & metabolism (33) 33
expression (33) 33
immunotherapy (33) 33
mice, inbred c57bl (33) 33
article (32) 32
basal-cell carcinoma (32) 32
biopsy (32) 32
dopamine agonists - therapeutic use (32) 32
drug eruptions - etiology (32) 32
antimalarials - therapeutic use (31) 31
disease (31) 31
genital warts (31) 31
psoriasis - pathology (31) 31
randomized controlled trials as topic (31) 31
pituitary neoplasms - drug therapy (30) 30
retrospective studies (30) 30
bromocriptine - therapeutic use (29) 29
carcinoma in situ - drug therapy (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (804) 804
French (14) 14
German (7) 7
Russian (7) 7
Spanish (7) 7
Japanese (2) 2
Bulgarian (1) 1
Chinese (1) 1
Danish (1) 1
Hungarian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Psoriasiform Eruption and Oral Ulcerations as Adverse Effects of Topical 5% Imiquimod Treatment in Children: A Report of Four Cases
by Smith, Wallace A and Siegel, Dawn and Lyon, Valerie B and Holland, Kristen E
Pediatric Dermatology, ISSN 0736-8046, 11/2013, Volume 30, Issue 6, pp. e157 - e160
Imiquimod 5% cream is a topical immune‐response modifier indicated in the treatment of multiple cutaneous conditions including actinic keratoses, superficial... 
TRIAL | PEDIATRICS | CREAM | MOLLUSCUM CONTAGIOSUM | DERMATOLOGY | Drug Eruptions - etiology | Adjuvants, Immunologic - administration & dosage | Drug Eruptions - pathology | Humans | Aminoquinolines - administration & dosage | Child, Preschool | Oral Ulcer - chemically induced | Adjuvants, Immunologic - adverse effects | Psoriasis - pathology | Psoriasis - chemically induced | Female | Oral Ulcer - pathology | Administration, Topical | Child | Aminoquinolines - adverse effects | Warts | Complications and side effects | Skin | Imiquimod
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Aphthous vulvar ulcers: a paradoxal adverse effect at distance of topical imiquimod?
by Maroñas-Jiménez, Lidia and Morales-Raya, Carlos and Burillo-Martínez, Sara and Velasco-Tamariz, Virginia and Rodríguez-Peralto, Jose Luis and Vanaclocha-Sebastián, Francisco
European Journal of Obstetrics & Gynecology and Reproductive Biology, ISSN 0301-2115, 2015, Volume 198, pp. 156 - 157
Obstetrics and Gynecology | CREAM | REPRODUCTIVE BIOLOGY | OBSTETRICS & GYNECOLOGY | Vulvar Diseases - chemically induced | Imiquimod | Humans | Female | Immunologic Factors - adverse effects | Administration, Topical | Ulcer - chemically induced | Condylomata Acuminata - drug therapy | Aminoquinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Adverse effects of Aldara (R): Polymorphous erythema and chronic ulceration
by Schmutz, JL
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, ISSN 0151-9638, 01/2015, Volume 142, Issue 1, pp. 78 - 79
DERMATOLOGY | Erythema - chemically induced | Skin Ulcer - chemically induced | Antineoplastic Agents - adverse effects | Humans | Aminoquinolines - adverse effects
Journal Article
Details down arrow
4. Full Text Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation
by Kumar, Bhushan and Narang, Tarun
Sexually Transmitted Infections, ISSN 1368-4973, 08/2011, Volume 87, Issue 5, pp. 432 - 432
INFECTIOUS DISEASES | MECHANISMS | Arthralgia - immunology | Adjuvants, Immunologic - administration & dosage | Prospective Studies | Humans | Aminoquinolines - administration & dosage | Male | Arthralgia - chemically induced | Fever - chemically induced | Adjuvants, Immunologic - adverse effects | Headache - immunology | Adult | Immunocompetence | Fever - immunology | Headache - chemically induced | Immunity, Cellular | Ointments | Condylomata Acuminata - drug therapy | Aminoquinolines - adverse effects | Complications and side effects | Imiquimod
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases
by Rosenblatt, A and De Campos Guidi, H G
International Journal of STD & AIDS, ISSN 0956-4624, 12/2012, Volume 23, Issue 12, pp. 909 - 910
Imiquimod is a topical immune response modifier used to treat anogenital warts. Although considered a safe drug, mild to moderate local and systemic... 
Anogenital warts | Adverse effects | Imiquimod | HPV | INFECTIOUS DISEASES | STIMULATION | imiquimod | adverse effects | IMMUNOLOGY | anogenital warts | Antiviral Agents - therapeutic use | Antiviral Agents - adverse effects | Humans | Middle Aged | Condylomata Acuminata - virology | Male | Interferon Inducers - adverse effects | Aminoquinolines - therapeutic use | Condylomata Acuminata - drug therapy | Interferon Inducers - therapeutic use | Alphapapillomavirus - isolation & purification | Aminoquinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects
by Green, Justin A and Mohamed, Khadeeja and Goyal, Navin and Bouhired, Samia and Hussaini, Azra and Jones, Siôn W and Koh, Gavin C. K. W and Kostov, Ivan and Taylor, Maxine and Wolstenholm, Allen and Duparc, Stephan
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2016, Volume 60, Issue 12, pp. 7321 - 7332
Tafenoquine is in development as a single-dose treatment for relapse prevention in individuals with Plasmodium vivax malaria. Tafenoquine must be... 
RELAPSE | RIAMET(R) | VIVAX | SAFETY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | MEFLOQUINE | CLINICAL PHARMACOKINETICS | CHLOROQUINE | PLASMODIUM-FALCIPARUM MALARIA | PRIMAQUINE | INTERACTION TRIAL | Ethanolamines - adverse effects | Artemisinins - pharmacokinetics | Humans | Middle Aged | Half-Life | Male | Healthy Volunteers | Quinolines - pharmacokinetics | Young Adult | Ethanolamines - pharmacokinetics | Drug Interactions | Adult | Female | Fluorenes - adverse effects | Drug Therapy, Combination | Antimalarials - adverse effects | Fluorenes - pharmacokinetics | Antimalarials - pharmacokinetics | Plasmodium vivax - drug effects | Malaria, Vivax - drug therapy | Adolescent | Aged | Aminoquinolines - pharmacokinetics | Artemisinins - adverse effects | Quinolines - adverse effects | Aminoquinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity
by Rosemary Rochford and Colin Ohrt and Paul C. Baresel and Brice Campo and Aruna Sampath and Alan J. Magill and Babu L. Tekwani and Larry A. Walker
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2013, Volume 110, Issue 43, pp. 17486 - 17491
Individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency are at risk for the development of hemolytic anemia when given 8-aminoquinolines (8-AQs),... 
Hemolysis | Dehydrogenases | Malaria | Erythrocytes | Antimalarials | Mice | Drug design | Reticulocytes | Dosage | Blood | IMMUNOCOMPROMISED MICE | IMMUNODEFICIENT MICE | DRUG | TRANSMISSION | HUMAN MALARIA | SCID MICE | PLASMODIUM-FALCIPARUM | HUMAN ERYTHROCYTES | MULTIDISCIPLINARY SCIENCES | RED-BLOOD-CELLS | PRIMAQUINE | Dapsone - adverse effects | Humans | Transplantation, Heterologous | Dapsone - therapeutic use | Erythrocyte Transfusion - methods | Dose-Response Relationship, Drug | Mefloquine - therapeutic use | Sensitivity and Specificity | Female | Doxycycline - adverse effects | Pyrimethamine - therapeutic use | Antimalarials - adverse effects | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Glucosephosphate Dehydrogenase Deficiency - blood | Pyrimethamine - adverse effects | Doxycycline - therapeutic use | Glucosephosphate Dehydrogenase Deficiency - therapy | Chloroquine - therapeutic use | Antimalarials - therapeutic use | Combined Modality Therapy | Chloroquine - adverse effects | Mice, SCID | Mefloquine - adverse effects | Animals | Primaquine - therapeutic use | Anemia, Hemolytic - diagnosis | Anemia, Hemolytic - chemically induced | Mice, Inbred NOD | Primaquine - adverse effects | Anemia, Hemolytic - blood | Aminoquinolines - therapeutic use | Erythrocyte Count | Aminoquinolines - adverse effects | Phosphates | Physiological aspects | Oxidoreductases | Anemia | Health aspects | Risk factors | Index Medicus | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A randomised study of topical 5 imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up
by Krawtchenko, N and Roewert-Huber, J and Ulrich, M and Mann, I and Sterry, W and Stockfleth, E
British Journal of Dermatology, ISSN 0007-0963, 12/2007, Volume 157, Issue s2, pp. 34 - 40
Summary Background  Actinic keratoses (AK) frequently occur on sun-exposed skin and are considered as in situ squamous cell carcinoma. To date, no treatment... 
5-fluorouracil | actinic keratoses | comparative study | cryosurgery | imiquimod | field cancerisation | 5‐fluorouracil | Field cancerisation | 5-Fluorouracil | Cryosurgery | Actinic keratoses | Imiquimod | Comparative study | EFFICACY | PERSPECTIVE | SOLAR KERATOSIS | FLUOROURACIL | FORMULATION | DERMATOLOGY | TRIAL | THERAPY | CREAM | SQUAMOUS-CELL CARCINOMA | DOUBLE-BLIND | Neoplasms, Radiation-Induced - surgery | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Middle Aged | Carcinoma, Squamous Cell - surgery | Male | Antineoplastic Agents - therapeutic use | Keratosis - drug therapy | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Immunocompetence | Skin Neoplasms - surgery | Esthetics | Treatment Outcome | Neoplasms, Radiation-Induced - drug therapy | Ultraviolet Rays - adverse effects | Carcinoma, Squamous Cell - drug therapy | Aged | Cryosurgery - adverse effects | Aminoquinolines - therapeutic use | Aminoquinolines - adverse effects | Medical research | Algorithms | Surgery | Patient outcomes | Medicine, Experimental | Comparative analysis | Fluorouracil | Keratosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis
by Zanvit, Peter and Konkel, Joanne E and Jiao, Xue and Kasagi, Shimpei and Zhang, Dunfang and Wu, Ruiqing and Chia, Cheryl and Ajami, Nadim J and Smith, Daniel P and Petrosino, Joseph F and Abbatiello, Brittany and Nakatsukasa, Hiroko and Chen, Qianming and Belkaid, Yasmine and Chen, Zi-Jiang and Chen, Wanjun
Nature Communications, ISSN 2041-1723, 09/2015, Volume 6, Issue 1, p. 8424
Psoriasis is an inflammatory skin disease affecting similar to 2% of the world's population, but the aetiology remains incompletely understood. Recently,... 
INTESTINAL MICROBIOTA | MULTIDISCIPLINARY SCIENCES | DISEASE | DELTA T-CELLS | MICE | MECHANISMS | GUT MICROBIOTA | HEALTH | SKIN INFLAMMATION | IMIQUIMOD | LYMPHOCYTES | Animals, Newborn | Disease Susceptibility | Psoriasis - drug therapy | Imiquimod | Polymyxin B - adverse effects | Mice, Inbred C57BL | Microbiota - drug effects | Interleukins - metabolism | Vancomycin - adverse effects | Interleukin-17 - metabolism | Animals | Drug Interactions | T-Lymphocytes - metabolism | Psoriasis - chemically induced | Psoriasis - metabolism | Anti-Bacterial Agents - adverse effects | Mice | Aminoquinolines | Skin - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Aldara activates TLR7-independent immune defence
by Walter, Anne and Schäfer, Matthias and Cecconi, Virginia and Matter, Claudia and Urosevic-Maiwald, Mirjana and Belloni, Benedetta and Schönewolf, Nicola and Dummer, Reinhard and Bloch, Wilhelm and Werner, Sabine and Beer, Hans-Dietmar and Knuth, Alexander and Van Den Broek, Maries
Nature Communications, ISSN 2041-1723, 2013, Volume 4, Issue 1, p. 1560
Aldara is a cream used for topical treatment of non-melanoma skin cancer, and is thought to act through stimulation of anti-tumour immunity. The active... 
SQUAMOUS-CELL | ROR-GAMMA-T | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | BASAL-CELL CARCINOMA | RESPONSE MODIFIER | RECEPTOR | MICE | GENERATION | EXPRESSION | IMIQUIMOD | Inflammasomes - metabolism | Skin Neoplasms - drug therapy | Apoptosis - drug effects | Humans | Interferon Type I - immunology | RNA, Messenger - metabolism | Immunity - drug effects | Toll-Like Receptor 7 - immunology | Keratosis, Actinic - immunology | Aminoquinolines - pharmacology | Neutrophil Infiltration - drug effects | Skin Neoplasms - pathology | Epidermis - pathology | Cytokines - metabolism | Skin Neoplasms - immunology | Epidermis - drug effects | RNA, Messenger - genetics | Cells, Cultured | Immunity - immunology | Carcinoma, Basal Cell - pathology | Carcinoma, Basal Cell - immunology | Keratinocytes - immunology | Gene Expression Regulation - drug effects | Up-Regulation - drug effects | Keratinocytes - pathology | Models, Immunological | Animals | Epidermis - immunology | Keratinocytes - drug effects | Keratosis, Actinic - drug therapy | Epidermis - ultrastructure | Carcinoma, Basal Cell - drug therapy | Cell Proliferation - drug effects | Mice | Aminoquinolines - therapeutic use | Keratosis, Actinic - pathology | Aminoquinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Low systemic exposure and calcemic effect of calcipotriol/betamethasone ointment in rats with imiquimod-induced psoriasis-like dermatitis
by Satake, Kyosuke and Amano, Toru and Okamoto, Tadao
European Journal of Pharmacology, ISSN 0014-2999, 05/2018, Volume 826, pp. 31 - 38
Vitamin D (VD ) analogues-containing ointments are known to occasionally cause hypercalcemia in psoriasis patients, and the frequency of hypercalcemia is... 
Systemic exposure | Calcemic effect | Vitamin D receptor target gene | Skin atrophy | Psoriasis | Vitamin D3-containing ointment | Vitamin D | containing ointment | CELLS | GLUCOCORTICOIDS | Vitamin D-3-containing ointment | ANALOG | MECHANISMS | CA2+ TRANSPORT | GENES | PHARMACOLOGY & PHARMACY | 1,25-DIHYDROXYVITAMIN D-3 | SKIN | VULGARIS | EXPRESSION | Rats, Wistar | Calcium - metabolism | Imiquimod | Humans | Calcitriol - adverse effects | Aminoquinolines - toxicity | Male | Administration, Cutaneous | Dermatologic Agents - adverse effects | Calcitriol - analogs & derivatives | Calcium - blood | Rats, Hairless | Hypercalcemia - blood | Betamethasone - adverse effects | Psoriasis - blood | Ointments | Skin - pathology | Disease Models, Animal | Psoriasis - drug therapy | Betamethasone - analogs & derivatives | Rats | Hypercalcemia - chemically induced | Receptors, Calcitriol - metabolism | Animals | Dihydroxycholecalciferols - adverse effects | Psoriasis - chemically induced | Atrophy - blood | Atrophy - chemically induced | Clobetasol - adverse effects | Drug Combinations | Skin - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT‐1 study
by Marsden, J.R and Fox, R and Boota, N.M and Cook, M and Wheatley, K and Billingham, L.J and Steven, N.M and Simpkins, D and Whitham, D and Chalmers, J and Bunker, C and Wharton, S and Brothwell, S and Hague, L and Harwood, C and Ives, N and Ramsay, H and Burrows, L and Proby, C and Motley, R and Levell, N and Lucke, T and Zaki, I and Gupta, G and Collucci, L and Williams, J and Steele, J and NCRI Skin Canc Clinical Studies and LIMIT-1 Collaborative Grp and UK Dermatology Clinical Trials and NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group and the NCRI Skin Cancer Clinical Studies Group, the U.K. Dermatology Clinical Trials Network and the LIMIT-1 Collaborative Group
British Journal of Dermatology, ISSN 0007-0963, 05/2017, Volume 176, Issue 5, pp. 1148 - 1154
What's already known about this topic? Imiquimod can cause clinical regression of lentigo maligna (LM). What does this study add? The pathological complete... 
MELANOMA IN-SITU | MANAGEMENT | THERAPY | EFFICACY | CREAM | FOLLOW-UP | RADIOTHERAPY | EXCISION | 5-PERCENT | DERMATOLOGY | Hutchinson's Melanotic Freckle - drug therapy | Skin Neoplasms - drug therapy | Humans | Middle Aged | Aminoquinolines - administration & dosage | Male | Treatment Outcome | Administration, Cutaneous | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - adverse effects | Female | Aged | Aminoquinolines - adverse effects | Polymerase chain reaction | Addiction | Imiquimod | Biopsy | Surgery | Hyperplasia | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3 VIN): a multicentre, open-label, randomised, phase 2 trial
by Tristram, Amanda, MD and Hurt, Christopher N, MSc and Madden, Tracie, PhD and Powell, Ned, PhD and Man, Stephen, PhD and Hibbitts, Sam, PhD and Dutton, Peter, MSc and Jones, Sadie, MBBCh and Nordin, Andrew J, FRCOG and Naik, Raj, MD and Fiander, Alison, Prof and Griffiths, Gareth, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. 1361 - 1368
Summary Background Vulval intraepithelial neoplasia is a skin disorder affecting the vulva that, if left untreated, can become cancerous. Currently, the... 
Hematology, Oncology and Palliative Medicine | Cytosine - adverse effects | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Carcinoma in Situ - drug therapy | Carcinoma in Situ - pathology | Vulvar Neoplasms - drug therapy | Humans | Middle Aged | Aminoquinolines - administration & dosage | Organophosphonates - adverse effects | Cytosine - administration & dosage | Drug-Related Side Effects and Adverse Reactions - pathology | Organophosphonates - administration & dosage | Vulvar Neoplasms - pathology | Neoplasm Grading | Adult | Female | Aminoquinolines - adverse effects | Clinical trials | Medical colleges | Care and treatment | Papillomavirus infections | Target marketing
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies
by Geisse, John and Caro, Ivor and Lindholm, Jane and Golitz, Loren and Stampone, Patti and Owens, Mary
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2004, Volume 50, Issue 5, pp. 722 - 733
Background: Imiquimod is an immune response modifier that is a Toll-like receptor 7 agonist that induces interferon and other cytokines through the innate... 
DERMATOLOGY | Adjuvants, Immunologic - administration & dosage | Skin Neoplasms - drug therapy | Double-Blind Method | Humans | Middle Aged | Aminoquinolines - administration & dosage | Male | Interferon Inducers - adverse effects | Adjuvants, Immunologic - adverse effects | Aged, 80 and over | Carcinoma, Basal Cell - drug therapy | Adult | Female | Aged | Interferon Inducers - administration & dosage | Ointments | Aminoquinolines - adverse effects | Pharmaceutical Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice
by Van Belle, Astrid B and De Heusch, Magali and Lemaire, Muriel M and Hendrickx, Emilie and Warnier, Guy and Dunussi-Joannopoulos, Kyri and Fouser, Lynette A and Renauld, Jean-Christophe and Dumoutier, Laure
Journal of Immunology, ISSN 0022-1767, 01/2012, Volume 188, Issue 1, pp. 462 - 469
Psoriasis is a common chronic autoimmune skin disease of unknown cause that involves dysregulated interplay between immune cells and keratinocytes. IL-22 is a... 
ROR-GAMMA-T | DENDRITIC CELLS | DOUBLE-BLIND | INTERLEUKIN-22 | CYTOKINE | IMMUNOLOGY | EXPRESSION | 5-PERCENT CREAM | ACTINIC KERATOSIS | INNATE IMMUNITY | TH17 CELLS | Adjuvants, Immunologic - pharmacology | Chemokine CCL3 - immunology | Dermatitis - immunology | Skin - metabolism | Immunity, Innate - genetics | Receptors, Antigen, T-Cell, gamma-delta - genetics | Adjuvants, Immunologic - adverse effects | Interleukins - genetics | Chemokine CCL3 - genetics | Psoriasis - pathology | T-Lymphocytes - metabolism | Interleukins - immunology | Psoriasis - metabolism | Antigens, Differentiation - metabolism | Chemokine CCL3 - metabolism | Interleukins - biosynthesis | T-Lymphocytes - pathology | Aminoquinolines - pharmacology | Neutrophils - metabolism | Neutrophil Infiltration - drug effects | Skin - pathology | Disease Models, Animal | Neutrophil Infiltration - immunology | Neutrophils - pathology | Skin - immunology | Psoriasis - immunology | Immunity, Innate - drug effects | Receptors, Antigen, T-Cell, gamma-delta - metabolism | Gene Expression Regulation - genetics | Gene Expression Regulation - immunology | Neutrophils - immunology | Receptors, Antigen, T-Cell, gamma-delta - immunology | Neutrophil Infiltration - genetics | Mice, Knockout | Dermatitis - etiology | Immunity, Innate - immunology | Animals | Psoriasis - chemically induced | T-Lymphocytes - immunology | Antigens, Differentiation - genetics | Mice | Aminoquinolines - adverse effects | Antigens, Differentiation - immunology | Dermatitis - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant
by Adams, Sylvia and O'Neill, David W and Nonaka, Daisuke and Hardin, Elizabeth and Chiriboga, Luis and Siu, Kimberly and Cruz, Crystal M and Angiulli, Angelica and Angiulli, Francesca and Ritter, Erika and Holman, Rose Marie and Shapiro, Richard L and Berman, Russell S and Berner, Natalie and Shao, Yongzhao and Manches, Olivier and Pan, Linda and Venhaus, Ralph R and Hoffman, Eric W and Jungbluth, Achim and Gnjatic, Sacha and Old, Lloyd and Pavlick, Anna C and Bhardwaj, Nina
The Journal of Immunology, ISSN 0022-1767, 07/2008, Volume 181, Issue 1, pp. 776 - 784
T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs. In this study, we evaluated the safety... 
NONHUMAN-PRIMATES | T-CELL RESPONSES | CANCER-PATIENTS | DENDRITIC CELLS | CANCER/TESTIS ANTIGENS | TOLL-LIKE RECEPTORS | IMMUNOLOGY | DNA VACCINATION | 5-PERCENT CREAM | TUMOR-ANTIGEN | LANGERHANS CELLS | Epitope Mapping | Erythema - pathology | Adjuvants, Immunologic - pharmacology | Imiquimod | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Erythema - chemically induced | Adult | Female | Aminoquinolines - pharmacology | Erythema - immunology | Melanoma - metabolism | Toll-Like Receptor 7 - agonists | Antibody Formation - immunology | Immunization | Toll-Like Receptor 7 - metabolism | Antigens, Neoplasm - immunology | Cancer Vaccines - adverse effects | Membrane Proteins - immunology | Melanoma - pathology | Cancer Vaccines - immunology | Pilot Projects | Biopsy | Melanoma - immunology | Aged | Melanoma - therapy | Aminoquinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis
by Flutter, Barry and Nestle, Frank O
European Journal of Immunology, ISSN 0014-2980, 12/2013, Volume 43, Issue 12, pp. 3138 - 3146
Psoriasis is an inflammatory disease of the skin affecting 2–3% of the population, characterized by a thickening of the epidermis and immune infiltrates... 
Animal models | TLR7 | Psoriasis | Imiquimod | DENDRITIC CELLS | DELTA T-CELLS | IMMUNOLOGY | IL-22 | LANGERHANS CELLS | DISEASE | PLAQUE-FORMATION | IMMUNE-RESPONSE MODIFIER | POTENTIAL ROLE | SKIN INFLAMMATION | ACTINIC KERATOSIS | Psoriasis - immunology | Toll-Like Receptor 7 - agonists | Adjuvants, Immunologic - pharmacology | Humans | Membrane Glycoproteins - agonists | Adjuvants, Immunologic - adverse effects | Toll-Like Receptor 8 - immunology | Animals | Psoriasis - pathology | Psoriasis - chemically induced | Toll-Like Receptor 7 - immunology | Mice | Membrane Glycoproteins - immunology | Aminoquinolines - pharmacology | Receptors, Purinergic P1 - immunology | Aminoquinolines - adverse effects | Cytokines - immunology | Disease Models, Animal | Toll-Like Receptor 8 - agonists | Skin | Analysis | Medical research | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights